FOLH1 and prostate cancer: This same group (Emfietzoglou et al. 2005) estimated the dosimetry of the β-particle emitters, 32P, 90Y, 188Re, 67Cu or 131I or AE-emitters, 123I or 125I incorporated into SUV (50–100 nm) or MLV (80–1000 nm) liposomes modified with anti-PSMA J591 antibodies and incubated in vitro with LNCaP human prostate cancer spheroids (200 μm diameter).